Printer Friendly
The Free Library
14,551,487 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Diamics Submits 510k to FDA for Unique Cervical Collection Device.


NOVATO, Calif. -- Diamics, Inc., a San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden  Bay-area, medical device and diagnostics company, today announced it has submitted a 510(k) premarket notification application to the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 for its proprietary CerCol cervical collection device. The CerCol device is designed to improve screening for cervical cancer Cervical Cancer Definition

Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors.
 and greater comfort to the patient.

The CerCol collector is designed to capture a mirror image sample from 360 degrees of the endocervical canal, the ectocervical area and the transformation zone of the cervix cervix /cer·vix/ (ser´viks) pl. cer´vices   [L.]
1. neck.

2. the front portion of the neck.

3. cervix uteri.
 with a single device. When the CerCol is placed in the cervix, its reusable handle allows for the rotation of the disposable collector tip.

The CerCol has been developed to be used both as part of a standard, liquid-based Pap test Pap test, Pap smear, or Papanicolaou test (păp'ənē`kəlou), medical procedure used to detect cancer of the uterine cervix.  and as a component of Diamics' C-Map cervical cancer screening system. When used in the C-Map system, the collector captures a unique cervical sample which is transferred to a slide, exposed to a proprietary antibody assay and read by a fully-automated scanner. The scanner then generates a representative map of the cervix and shows the general location of any precancerous precancerous /pre·can·cer·ous/ (-kan´ser-us) pertaining to a pathologic process that tends to become malignant.

pre·can·cer·ous
adj.
 lesions.

The 510(k) application used data from a clinical trial that measured cellularity, (whether a sufficient number of cells was collected), adequacy (the presence of cells representative of the endocervix and transformation zone - the two areas of the cervix where cervical cancer typically starts), reporting according to the Bethesda Classification System, and patient comfort. The collector sample in the clinical trial supporting the 510(k) application was put into a liquid-based preservative preservative

Any of numerous chemical additives used to prevent or slow food spoilage caused by chemical changes (e.g., oxidation, mold growth) and maintain a fresh appearance and consistency. Antimycotics (e.g.
 for Pap analysis, More than 250 women undergoing an annual gynecological gynecological /gy·ne·co·log·i·cal/ (-kah-loj´i-k'l) gynecologic.  exam participated in the study at multiple sites.

FDA 510(k) applications serve as a screening mechanism to allow for marketing of medical devices with a reasonable assurance of safety and effectiveness.

About Diamics, Inc.

Diamics Inc. is a privately owned medical device and diagnostics company located in Novato, California. The company is committed to developing, manufacturing, and marketing cost-effective, molecular-based cancer screening and diagnostic systems that will increase long-term survival rates through early detection. Diamics has a mature management team with an extensive track record in the medical device and diagnostics industries. The company's goals are to help medical personnel worldwide improve lives and to create value for investors, employees and all who use and benefit from its proprietary technology. Please visit www.diamics.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 21, 2006
Words:390
Previous Article:Juniper Networks Application Acceleration Platforms Achieve ''Ready for IBM'' Validation; DX, WX, WXC Solutions Certified Interoperable With Lotus...
Next Article:SecurePipe Announces mailMAX Channel Partner Program for Email Compliance, Security and Increased Revenue; Partners Rewarded With a Competitive...
Topics:



Related Articles
Preventing pregnancy with the cervical cap.
Approval processes different for devices and drugs. (Health Care Technology)
Enhancing efficiency: step by step. (medical law)
Cervical cap fitting.
Breast implants, Hippocrates, and burden of proof. (Health Care Technology)
LDR Spine Secures FDA Approval to Conduct the First Clinical Trial for a Second-Generation Cervical Artificial Disc.
North American Scientific Launches Breast Brachytherapy Initiative.
Diamics Inc.'s Proprietary Cervical Cancer Screening System to Be Presented at AACC Clinical Lab Expo.
Richard J. Cote, M.D. Named Chief Medical Officer and Executive Vice President of Diamics, Inc.
LDR Medical Reaches Milestone of Over 3,000 Artificial Discs Worldwide.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles